MBB Public Markets I LLC Takes $284,000 Position in DexCom, Inc. $DXCM

Key Points

• MBB Public Markets I LLC has acquired a stake of 4,154 shares in DexCom, Inc. valued at approximately $284,000 during the first quarter.
• A significant majority of the stock, approximately 97.75%, is currently owned by institutional investors, indicating strong institutional interest in DexCom.
• Analysts have a favorable outlook for DexCom, with a consensus rating of Moderate Buy and an average price target of $99.89.

MBB Public Markets I LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,154 shares of the medical device company's stock, valued at approximately $284,000.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of DexCom by 2.0% during the first quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company's stock valued at $3,240,763,000 after buying an additional 925,882 shares during the last quarter. Jennison Associates LLC lifted its position in shares of DexCom by 37.7% during the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock valued at $718,632,000 after buying an additional 2,879,489 shares during the last quarter. Nuveen LLC purchased a new stake in shares of DexCom during the first quarter valued at about $554,893,000. Raymond James Financial Inc. lifted its position in shares of DexCom by 21.8% during the first quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company's stock valued at $229,117,000 after buying an additional 601,088 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of DexCom by 171.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock valued at $218,175,000 after buying an additional 2,015,971 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director directly owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. The trade was a 5.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,237 shares of company stock worth $1,263,480 in the last ninety days. 0.32% of the stock is owned by company insiders.

DexCom Stock Performance

DXCM traded up $0.22 during trading on Friday, reaching $76.22. 3,054,556 shares of the company's stock were exchanged, compared to its average volume of 4,029,013. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The stock has a market capitalization of $29.89 billion, a P/E ratio of 52.93, a price-to-earnings-growth ratio of 1.60 and a beta of 1.48. The company's fifty day simple moving average is $80.88 and its 200-day simple moving average is $78.58.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the firm posted $0.43 EPS. DexCom's revenue for the quarter was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on DXCM. William Blair raised shares of DexCom to a "strong-buy" rating in a research report on Thursday, July 31st. Barclays lifted their target price on shares of DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Wall Street Zen cut shares of DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Piper Sandler lifted their target price on shares of DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. Finally, UBS Group lifted their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $99.89.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.